Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S043 - Acne Treatment Controversies

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Formulate a comprehensive and effective acne management plan for their patients with acne, incorporating the latest published data and guidelines.
  • Recognize the psychosocial impact of acne as well as the ethical considerations involved in the care of acne patients.

Description

In this session, the speakers will tackle the top controversies in acne treatment. Questions to be addressed include: Is antibiotic resistance something we need to worry about? Do oral contraceptives work as well as systemic antibiotics in treating acne? What are the contraceptive requirements for IPledge in transgender patients? Does isotretinoin induce depression or make it worse? What is the ideal dosing and duration for isotretinoin? Is more better? What does topical clindamycin add to the routine? For acne fulminans, at what dose and when should isotretinoin be started? What is the ideal time to start treatment of acne scarring?

Disclosures

  • Friedlander, Sheila Fallon, MD: no financial relationships exist with commercial interests.
  • Graber, Emmy M., MD, MBA: 3Derm Systems – C(H); Allergan, Inc – A(H); Almirall – C(H); Castle Creek Pharmaceuticals – C(H); Sol-Gel Technologies – C(H);
  • Keri, Jonette Elizabeth, MD, PhD: Hoffman-La Roche Ltd. – C(Fees); Ortho Dermatologics – A(H); Pierre Fabre Dermatologie – A(H);
  • Kirby, Joslyn S., MD: AbbVie – SP(H); Incyte Corporation – C(H);
  • Ortiz, Arisa, MD: Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – C(H); Guthy-Renker – SP(S); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Sienna Biopharmaceuticals – I(Grants/Research Funding); Ulthera – Data Safety Monitoring Board(H);
  • Reynolds, Rachel Victoria Sabbag, MD: Biosense Webster – C(Fees); Edwards Lifesciences – C(Fees); Medtronics – C(Fees);
  • Stoff, Benjamin, MD: no financial relationships exist with commercial interests.
  • Zaenglein, Andrea L., MD: Allergan, Inc – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Astellas Pharma US, Inc – I(Grants/Research Funding); Cassiopea S.p.A. – C(Fees); Dr. Reddy – C(Fees); Innovaderm Research Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H);
Schedule
Sunday, February 18
1:00 PM
Dr. Keri / Psychosocial impact of acne
1:20 PM
Dr. Kirby / Use of antibiotics in acne
1:40 PM
Dr. Reynolds / Use of hormonal therapies in acne
2:00 PM
Dr. Stoff / Ethics in acne
2:20 PM
Dr. Keri, Dr. Reynolds, Dr. Kirby, and Dr. Stoff / Q&A
2:30 PM
Dr. Zaenglein / Isotretinoin dosing, duration and lab monitoring
2:50 PM
Dr. Friedlander / Management of acne fulminans and variants
3:10 PM
Dr. Graber / Topical treatment of acne
3:30 PM
Dr. Ortiz / Management of acne scarring
3:50 PM
Dr. Zaenglein, Dr. Friedlander, Dr. Graber, and Dr. Ortiz / Q&A
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 6A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Andrea L. Zaenglein, MD, FAAD
Speakers
  • Arisa Ortiz, MD, FAAD - Handout
  • Benjamin Stoff, MD, FAAD - Handout
  • Emmy M. Graber, MD, MBA, FAAD
  • Jonette Elizabeth Keri, MD, PhD, FAAD - Handout
  • Joslyn S. Kirby, MD, FAAD
  • Rachel Victoria Sabbag Reynolds, MD, FAAD - Handout
  • Sheila Fallon Friedlander, MD, FAAD